Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers in the United States have described a novel antiviral agent against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being evaluated in clinical trials as a treatment for coronavirus disease 2019 (COVID-19).

2 Aug 2021

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

A pioneering study reports on the interaction of a tailored titanium oxide nanoparticle (NP) with the full-length SARS-CoV-2 non-structural protein 1 (nsp1). This should be of value in developing new therapeutic tools against coronaviruses that act by targeting their proteins. It could also help map the structure of activated proteins.

2 Aug 2021

Polyuridine sequence of mouse coronavirus can be targeted to prevent host cell death

A new study reports the use of a modified deoxyribonucleic acid (DNA) oligonucleotide that has a 3’ polyadenine (polyA) tail to bind to the 5’-polyU tract in the mouse coronavirus (MHV-A59). Treatment of mouse cells infected with MHV-A59 with this molecule led to a marked reduction in cell deaths.

2 Aug 2021

Could novel biosensors facilitate SARS-CoV-2 antiviral drug research?

An intriguing new study presents a novel approach to biosensor-based evaluation of promising drugs that could inhibit the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via its 3C-like protease (3CLpro), a viral protease.

2 Aug 2021

Intradermal administration of low-dose mRNA COVID-19 vaccine induces strong immune response, study finds

Scientists in the Netherlands recently conducted an open-level, randomized-controlled trial to evaluate the safety and immunogenicity of fractional intradermal doses of the mRNA-based COVID-19 vaccine mRNA-1273 (Moderna). The trial findings reveal that the fractional dose regimen of the Moderna vaccine is well tolerated and safe and is capable of inducing robust antibody responses in vaccine recipients. The study is currently available on the medRxiv* preprint server.

2 Aug 2021

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

Study examined 1,497 full-vaccinated healthcare workers for breakthrough infections

A new study published in The New England Journal of Medicine found that in a very small number of cases, people with breakthrough infections might suffer long-lasting COVID-19 symptoms.

2 Aug 2021

Older adults with prior SARS-CoV-2 infection benefit from two doses of Pfizer/BioNTech vaccine

The study by researchers from the Ministry of Health, Madrid, Spain, published in the Center of Disease Control and Prevention’s journal Emerging Infectious Diseases, suggests that long-term care facility residents with prior SARS-CoV-2 infection benefit from full vaccination with the Pfizer/BioNTech (BNT162b2) vaccine.

2 Aug 2021

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

The Centers for Disease Control and Prevention (CDC) issued a letter detailing a case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised patient who did not respond well to monoclonal antibody treatment. The resistance to treatment stemmed from an escape mutation on the spike protein known as Q4923R.

2 Aug 2021

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.

2 Aug 2021

Oh deer! Antibodies to SARS-CoV-2 detected in 40% of wild white-tailed deer in four U.S. states

Researchers conducting a serosurveillance study of a North American deer species have provided evidence of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among the animals across four U.S. states.

1 Aug 2021

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Researchers in the United States have conducted a study showing the difference in antibody evolution following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between people who have not previously been infected with the virus and those who have.

1 Aug 2021

Fighting SARS-CoV-2 with nanomedicine

Published in the Journal of Controlled Release, researchers from the German University in Cairo, and the University of Cologne, looked into nano-reformulation of repurposed antiviral and immune-modulating drugs for inhalation therapy against COVID-19. In addition, they focused on how nanomedicine could address the limitations of current therapeutics, enhancing the efficacy, specificity, and safety of such drugs.

1 Aug 2021

Risk of myocarditis from SARS-CoV-2 infection is higher in young males, a study finds

The study highlights that young males with COVID-19 are more susceptible to develop myocarditis than those who received mRNA-based COVID-19 vaccines.

1 Aug 2021

Finding potential microRNAs from humans and plants against SARS-CoV-2

A new study focuses on the identification of probable miRNA candidates from three medicinal plants.

1 Aug 2021

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

Considering the antiviral activity of medicinal herbs, a new study published in the journal Current Pharmacology Reports focuses on the identification of potent phytochemicals from Himalayan herbs, namely, Rheum emodi, Thymus serpyllum, and Artemisia annua, for the treatment of COVID-19.

1 Aug 2021

BNT162b2 vaccine shows high efficacy at six months

The Pfizer/BioNTech vaccine appears to be highly effective in protecting against the SARS-CoV-2 infection, including its relatively resistant beta variant B.1.351.

30 Jul 2021

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

A new study reports that the Johnson and Johnson vaccine against COVID-19 shows enhanced efficacy when administered to individuals with pre-existing antibodies.

30 Jul 2021

In-silico prediction of effective drug combinations for the treatment of SARS-CoV-2 infection

A new study published on the bioRxiv preprint server has developed the first computational model, i.e., a signaling network model, that can predict effective repurposed drug combinations to treat different phases of COVID-19 disease. This study has focused on identifying drugs for the treatment of early- and late-stage severe disease.

30 Jul 2021

Scientists suspect Lambda SARS-CoV-2 variant most dangerous

A new study published on the bioRxiv* preprint server used molecular phylogenetic analysis to study the evolutionary trait of the Lambda variant.

30 Jul 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Pfizer moves towards an oral anti-COVID-19 therapy

Researchers discover titanium oxide nanoparticle that recognizes SARS-CoV-2’s non-structural protein 1

Polyuridine sequence of mouse coronavirus can be targeted to prevent host cell death

Could novel biosensors facilitate SARS-CoV-2 antiviral drug research?

Intradermal administration of low-dose mRNA COVID-19 vaccine induces strong immune response, study finds

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

Study examined 1,497 full-vaccinated healthcare workers for breakthrough infections

Older adults with prior SARS-CoV-2 infection benefit from two doses of Pfizer/BioNTech vaccine

SARS-CoV-2 Q493R protein mutation shows resistance to monoclonal antibodies

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Oh deer! Antibodies to SARS-CoV-2 detected in 40% of wild white-tailed deer in four U.S. states

Antibody responses following SARS-CoV-2 infection more potent than vaccine-elicited ones

Fighting SARS-CoV-2 with nanomedicine

Risk of myocarditis from SARS-CoV-2 infection is higher in young males, a study finds

Finding potential microRNAs from humans and plants against SARS-CoV-2

Study looks at potent phytocompounds from Himalayan herbs to treat COVID-19

BNT162b2 vaccine shows high efficacy at six months

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

In-silico prediction of effective drug combinations for the treatment of SARS-CoV-2 infection

Scientists suspect Lambda SARS-CoV-2 variant most dangerous

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in